MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Ophthalmology, Optometry & Ocular Health (BioPharmaceuticals & Biotechnology)
Tarsus Pharmaceuticals, Inc (NASDAQ: TARS)*
Organization & Developments: Tarsus Pharmaceuticals
Parents
Tarsus Pharmaceuticals, Inc (NASDAQ: TARS)*
Children
2020: Tarsus Pharmaceuticals Seeks $80 Million In U.S. IPO
2022: Tarsus lead product candidate, TP-03, is an investigational eye drop in Phase III to treat blepharitis
2023: Tarsus Pharmaceuticals: 3 Clinical Catalysts In The Next 4 Months, Xdemvy Launch Underway_seekingalpha.com
2023: Tarsus Pharmaceuticals: Worthy Of A Small Bet (NASDAQ:TARS)
2024: Tarsus 'firing on all cylinders' as Xdemvy launch, sales force expansion roll ahead: CEO
2024: Tarsus Pharmaceuticals & SpringWorks Therapeutics: Jonathan Faison's Top 2 Picks
2024: Tarsus Pharmaceuticals: A Strong Launch For An Under The Radar Name
2024: Tarsus Pharmaceuticals: Early Rollout Exceeding Expectations_seekingalpha.com
2024: Tarsus Pharmaceuticals: Strong Execution In Eye Disease Treatment
2024: Tarsus Pharmaceuticals: Unlocking Growth Potential With Eye Care Innovations_ seekingalpha.com
2024: Tarsus Pharmaceuticals’ Xdemvy demonstrates positive efficacy and safety in treatment for patients with Demodex blepharitis.
2025: Tarsus Pharma: Strong Execution In Xdemvy Commercialization
2025: Tarsus: Promising Investment, But Timing Is The Key
Jumps
Finance & Acquisition: Tarsus Pharmaceuticals
Key People: Tarsus Pharmaceuticals